news

Application of cell factory in the preparation of herpes zoster vaccine

Mon Jun 27 11:48:56 CST 2022

Vaccines play an irreplaceable role in the prevention and control of human diseases, and the vaccine industry has become an indispensable sub-field in the field of biomedicine. In the vaccine preparation process, the cell factory is a commonly used cell culture consumable, and this container is used in the preparation of the shingles vaccine.

Shingles is an acute infectious skin disease caused by the varicella-zoster virus. Chickenpox develops when children who are not immune to the virus become infected. Some patients become carriers of the virus after being infected without developing symptoms. Due to the neurotropic nature of the virus, it can be latent in the neurons of the dorsal root ganglion of the spinal cord for a long time after infection. When the resistance is low or fatigue, infection, or a cold, the virus can grow and multiply again, and move to the skin along the nerve fibers. Causes intense inflammation of the affected nerves and skin. Getting vaccinated in advance can prevent the occurrence of diseases.

The herpes zoster vaccine is a vaccine prepared by using 2BS (human embryonic lung diploid) cells. 2BS cells are a limited cell line isolated and identified from human embryonic lung tissue. It has been passaged for 25 generations and can support a variety of human sources. Virus replication, widely used in basic virology research. In terms of ease of operation, 10-layer cell factories are used more in the preparation of herpes zoster vaccine.

The use of cell factories to prepare vaccines has the advantages of low risk of contamination, small footprint, and reduced corporate quality control costs and downstream purification costs. It has become an indispensable culture container in large-scale vaccine production.

The FAI climbed 5.9 percent year-on-year in the first 11 months of 2018, quickening from the 5.7-percent growth in Jan-Oct, the National Bureau of Statistics (NBS) said Friday in an online statement.

The key indicator of investment, dubbed a major growth driver, hit the bottom in August and has since started to rebound steadily.

In the face of emerging economic challenges home and abroad, China has stepped up efforts to stabilize investment, in particular rolling out measures to motivate private investors and channel funds into infrastructure.

Friday's data showed private investment, accounting for more than 60 percent of the total FAI, expanded by a brisk 8.7 percent.

NBS spokesperson Mao Shengyong said funds into weak economic links registered rapid increases as investment in environmental protection and agriculture jumped 42 percent and 12.5 percent respectively, much faster than the average.

In breakdown, investment in high-tech and equipment manufacturing remained vigorous with 16.1-percent and 11.6-percent increases respectively in the first 11 months. Infrastructure investment gained 3.7 percent, staying flat. Investment in property development rose 9.7 percent, also unchanged.